$FIHL

Fidelis Insurance (NYSE:FIHL) Given New $25.00 Price Target at UBS Group

UBS Group has raised its price target for Fidelis Insurance (NYSE:FIHL) to $25.00 from $24.00, maintaining a "buy" rating and implying a potential 33.44% upside. This follows Fidelis Insurance beating Q4 EPS estimates but missing revenue expectations, along with authorizing a $400 million share buyback program. Despite mixed analyst ratings, the consensus price target for FIHL is $22.36, with the stock currently trading around $18.74.

Original reporting
MarketBeat · MarketBeat
Published Mar 9, 2026, 9:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 9, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fidelis Insurance (NYSE:FIHL) Given New $25.00 Price Target at UBS Group — source image
Decision brief

The 30-second read

$FIHLBullishMed
01

Why it matters

The combination of earnings beat and buyback suggests management's optimistic outlook, which has been recognized by UBS with a higher price target.

02

Market read

The news is highly relevant for FIHL investors and could influence short-term trading strategies.

03

What to watch

Potential macroeconomic headwinds or sector-specific risks could dampen upside; earnings quality should be further analyzed.

Timing: Immediate to short-term (next 1-3 months)

Background

Fidelis Insurance reported Q4 earnings, beating EPS estimates but missing revenue expectations. The company also announced a $400 million share buyback, signaling confidence.

Company-level read

Ticker impact

$FIHLBullishMedium confidence
Context

The news pertains directly to Fidelis Insurance (NYSE:FIHL), with a significant price target increase and recent earnings report.

Expected impact

Moderate upward movement toward the new price target over the next 1-3 months.

Evidence & confidence

The price target increase coupled with earnings beat and buyback authorization suggests positive outlook. However, mixed analyst ratings and revenue miss introduce some uncertainty.

Market effects

Potential positive sentiment for the insurance sector, especially for companies with similar profiles.

Limited to US markets, with possible ripple effects in regional insurance stocks.

Low; primarily relevant to US-based insurance companies and investors.

Counterpoint

Some analysts may view the price target increase as overly optimistic, especially given revenue miss and mixed ratings.

Key entities

  • Fidelis Insurance

    A US-based insurance company listed on NYSE.

  • UBS Group

    Global financial services firm that increased its price target for FIHL.

Related articles

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).